Smith Thornton Advisors LLC purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 773 shares of the medical research company’s stock, valued at approximately $242,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Savvy Advisors Inc. boosted its position in Amgen by 4.8% during the second quarter. Savvy Advisors Inc. now owns 41,302 shares of the medical research company’s stock valued at $12,905,000 after acquiring an additional 1,902 shares during the last quarter. Scientech Research LLC grew its stake in Amgen by 442.1% in the second quarter. Scientech Research LLC now owns 4,955 shares of the medical research company’s stock valued at $1,548,000 after acquiring an additional 4,041 shares during the period. Lighthouse Investment Partners LLC bought a new stake in Amgen during the 2nd quarter valued at $15,155,000. Marathon Capital Management increased its position in shares of Amgen by 30.1% during the second quarter. Marathon Capital Management now owns 1,188 shares of the medical research company’s stock worth $371,000 after acquiring an additional 275 shares in the last quarter. Finally, MBB Public Markets I LLC raised its stake in shares of Amgen by 54.0% in the second quarter. MBB Public Markets I LLC now owns 75,712 shares of the medical research company’s stock worth $23,656,000 after purchasing an additional 26,553 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.
Amgen Stock Up 2.0 %
Shares of Amgen stock opened at $319.10 on Friday. The company’s 50 day moving average price is $328.94 and its 200-day moving average price is $307.00. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The stock has a market capitalization of $171.18 billion, a price-to-earnings ratio of 45.59, a P/E/G ratio of 2.98 and a beta of 0.61.
Amgen Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 2.82%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is currently 128.57%.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on AMGN shares. Bank of America boosted their target price on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Argus boosted their price objective on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price (up from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Finally, Oppenheimer restated an “outperform” rating and set a $380.00 price target on shares of Amgen in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $325.55.
Amgen Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
- Five stocks we like better than Amgen
- 3 Warren Buffett Stocks to Buy Now
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
- What is a Low P/E Ratio and What Does it Tell Investors?
- What Intuitive Machines’ Big NASA Contract Means for Investors
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- REITs on the Rise After Rate Cuts: Where to Invest Now
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.